Clinical Trial

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a randomized, Open-label, Phase Ib/IIa study to evaluate the efficacy and safety of SPH4336 monotherapy or in combination with Cadonilimab in the patients with selected advanced solid tumors.
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-05-31 -> 2026-12-31 2026-08-07
Trial Details
NCT Number NCT05944224
Lead Sponsor Shanghai Pharmaceuticals Holding Co., Ltd
Conditions Advanced Solid Tumors
Enrollment 63 participants
Start Date 2023-10-17
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-06